LaRive Bio is a clinical development and licensing organization founded in 2021 and based in Zug. We seek to identify, license in/acquire, develop and license out molecules in areas of significant unmet medical need, applying an abbreviated regulatory pathway. At present, focus lies on Neurology.
Products, services, technology
We aim for developing treatment options by means of improving on existing first line treatment in areas of significant unmet medical need. CLX-106, a promising molecule for treatment of Multiple Sclerosis, was selected and will enter phase I clinical development with a 505(b)2 regulatory pathway.
The core team in Zug cooperates with top tier CRO’s, regulatory and manufacturing partners.
By striving for delivering medicines that improve patient’s quality of life.
We put patient’s needs first!
Teams that manage to align purpose with pragmatism.
Solid experience from the biopharmaceutical industry, understanding the value of science in the clinical setting.
We are adding on clinical operations and licensing skills to our compact core team.
Trying to give patients better medicines.
Exchange of experience and thoughts and sharing success factors.
At this stage primarily investors for funding the next steps of our program.